Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets Hard-to-Treat cancers in early trial

NCT ID NCT06326411

Recruiting now Disease control Sponsor: Nested Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 participants who have run out of standard treatment options will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA MAPK PATHWAY GENE MUTATION MEK MUTATION MELANOMA NSCLC ONCOLOGY RAF GENE MUTATION RAS (KRAS OR NRAS) GENE MUTATION SOLID TUMOR, ADULT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Cabrini Health Limited

    RECRUITING

    Malvern, Victoria, 3144, Australia

    Contact Email: •••••@•••••

  • Cabrini Hospital

    RECRUITING

    Malvern, Victoria, 3144, Australia

    Contact Email: •••••@•••••

  • Columbia University Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact Email: •••••@•••••

  • Gallipoli Medical Research Centre- Greenslopes Private Hospital

    RECRUITING

    Greenslopes, Queensland, 120, Australia

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Memorial Slone Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • NEXT Oncology - Austin

    ACTIVE_NOT_RECRUITING

    Austin, Texas, 78758, United States

  • NEXT Oncology - Dallas

    ACTIVE_NOT_RECRUITING

    Dallas, Texas, 75039, United States

  • NEXT Oncology - Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Roswell Park

    RECRUITING

    Buffalo, New York, 14263, United States

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • START Moutain Region

    COMPLETED

    West Valley City, Utah, 84119, United States

  • Sarah Cannon Research Institute at Health ONE

    RECRUITING

    Denver, Colorado, 80218, United States

  • Scientia Clinical Research, Ltd

    COMPLETED

    Randwick, New South Wales, 2031, Australia

  • Southern Oncology Research Unit

    RECRUITING

    Adelaide, South Australia, 5042, Australia

  • The Kinghorn Cancer Center, St. Vincent's Health Network

    RECRUITING

    Darlinghurst, New South Wales, 2010, Australia

  • UCLA Hematology/Oncology

    RECRUITING

    Westwood, Los Angeles, California, 90024, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center

    RECRUITING

    San Francisco, California, 94158, United States

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Email: •••••@•••••

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • Yale Cancer Center

    COMPLETED

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.